Boltz Raises $110 Million to Scale AI Molecular Design

A gloved hand pouring blue liquid from a flask into a glass vessel in a laboratory

Photo: Hippopx (public domain). Illustrative image.

What happened. Boltz, an MIT spinout building AI models for molecular design, raised a $110 million Series A on 18 November 2026, led by Bessemer Venture Partners. Existing investors Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures doubled down, and new investors include Greycroft, F-Prime, Hummingbird and Benchling. Boltz is a public-benefit company founded in 2025, with a team of 40 scientists and engineers; the funding goes into compute, data and hiring. Its seed round was $28 million, in January 2026.

The models behind it. Boltz launched its proprietary models BoltzMol-1, for small-molecule hit discovery, and BoltzProt-1, for protein design, in June 2026. The company says molecular token usage among paying customers is up about 50 times since June — a company claim, shown on a chart on its blog. It also says its models cut the time to a validated hit from months to weeks and the cost from hundreds of thousands of dollars to as low as $10,000, a claim from Bessemer’s announcement. Boltz’s open-source models have more than 5 million downloads, according to Bessemer.

The customers are the signal. Boltz has signed partnerships with six of the world’s 20 largest pharmaceutical companies, naming Pfizer, GSK, Takeda and Bristol Myers Squibb, with commercial models also deployed at those companies plus DSM Firmenich. That is the part investors are paying for: not a research demo, but models already inside the drug pipelines of the biggest buyers in the industry. The round sits in the same week’s biotech-AI funding wave as Isomorphic Labs’ $5 billion Series C, though at a very different scale — Boltz is the specialist bet, Isomorphic the platform bet.

Why it matters. Drug discovery is one of the few AI markets where the customer, the budget and the measurable outcome are all unambiguous — a validated molecule, faster and cheaper. Boltz’s $110 million is small next to this week’s mega-rounds, but the customer list is the strongest evidence yet that AI-designed molecules have moved from papers to pipelines.

Sources

  • Boltz
  • Series A
  • AI drug discovery
  • Bessemer
  • biotech AI

Related articles